Stoke teases early efficacy data for possible PhIII dose in lead Dravet syndrome program
Late last year, Stoke Therapeutics put out early data for its lead program, noting a potential efficacy signal in a handful of Dravet syndrome patients. Now, the biotech is back with a first look at results from the dose it may ultimately take into a pivotal study.
Zeroing in on a subgroup of six patients examined at the highest dose so far — who had all received three doses — Stoke observed a median 55% reduction in convulsive seizure frequency. The reduction was seen between four weeks after patients got their first 45 mg dose and three months after receiving their third. They were among a total of 55 patients who had received at least one dose of the drug at any level.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
